A Phase 1 interventional study of CAL-101 and Placebo in Allergic Rhinitis, sponsored by Gilead Sciences. Completed at 1 site in Austria. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-10-23.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Rhinitis, Allergic with a site in Austria — 1 open to participants now, 2 under way, none of them phase 3. Rhinitis, Allergic · Austria.
Among the 18 studies in Rhinitis, Allergic with a site in Austria, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 1, and was the 4th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →1 of the 18 studies in Rhinitis, Allergic with a site in Austria is open now. Recruiting first, the newest first:
Sven Schneider, MD · Sites in Austria
Ages 60+ · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 54 across the 16 interventional studies, 86 across the 2 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 2 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Rhinitis, Allergic with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06459219Sven Schneider, MDFactors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Rhinitis, Allergic with a site in Austria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and effect of CAL-101 in subjects with allergic rhinitis.
A Phase I, randomized, double-blind crossover study of CAL-101, an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, in patients with allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has taken a prohibited medication within the specified interval prior to Visit 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CAL-101
Drug: Placebo
CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
Also known as: Idelalisib, GS-1101
Placebo capsules administered orally BID for 7 days
Evaluate the safety CAL-101 using adverse events, vital signs, clinical laboratory tests, spirometry and ECG
Time frame: Baseline to Day 35
Change from baseline in total nasal symptom score
Time frame: Baseline to Day 35
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib